Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Phase of Trial: Phase II
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Semaglutide (Primary) ; Liraglutide
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 10 Jun 2017 Biomarkers information updated
- 08 Nov 2016 Status changed from active, no longer recruiting to completed.
- 23 Feb 2016 Planned number of patients changed from 704 to 706 as reported by ClinicalTrials.gov record.